MUNICH — Neoadjuvant treatment with nivolumab and ipilimumab induced major pathologic response in 100% of patients with early-stage, mismatch repair-deficient colon cancers, according to results of the phase 2 NICHE trial presented at European Society for Medical Oncology Congress.
MUNICH — The combination of nivolumab and low-dose ipilimumab may become a new first-line treatment option for patients with microsatellite instability-high metastatic colorectal cancer, according to results from the phase 2 CheckMate-142 trial presented at European Society for Medical Oncology Congress.
MUNICH — Patients with HPV-positive, low-risk oropharyngeal cancer should undergo chemoradiotherapy instead of cetuximab plus radiotherapy, according to late-breaking study results presented at European Society for Medical Oncology Congress.
MUNICH — Pembrolizumab prolonged survival compared with standard first-line systemic therapy for patients with recurrent or metastatic head and neck cancer, according to late-breaking study results presented at European Society for Medical Oncology Congress.
MUNICH — A post-hoc analysis of the randomized phase 3 KEYNOTE-040 trial presented at European Society for Medical Oncology Congress showed a trend toward improved OS with pembrolizumab compared with three other standard treatments for recurrent head and neck squamous cell carcinoma.
MUNICH — The addition of SD-101 to pembrolizumab induced a promising response rate among patients with recurrent or metastatic head and neck squamous cell carcinoma who had not received prior anti-PD-1 therapy, according to study results presented at European Society for Medical Oncology Congress.
MUNICH — Vandetanib induced tumor shrinkage that persisted throughout multiple treatment lines for patients with advanced unresectable medullary thyroid cancer, according to study results presented at European Society for Medical Oncology Congress.
MUNICH — The combination of lenvatinib and pembrolizumab appeared effective for a small cohort of patients with metastatic anaplastic or poorly differentiated thyroid carcinoma, according to study results presented at European Society for Medical Oncology Congress.
MUNICH — Maintenance olaparib significantly improved PFS among women with advanced ovarian cancer who harbored BRCA1 or BRCA2 mutations, according to results of the randomized phase 3 SOLO1 trial presented at European Society of Medical Oncology Congress.
